Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma

被引:71
作者
Kondo, Naru [1 ]
Murakami, Yoshiaki [1 ]
Uemura, Kenichiro [1 ]
Sudo, Takeshi [1 ]
Hashimoto, Yasushi [1 ]
Sasaki, Hayato [1 ]
Sueda, Taijiro [1 ]
机构
[1] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, Hiroshima 7348551, Japan
关键词
cholangiocarcinoma; CA19-9; predictive marker; surgical resection; CHEMOTHERAPY IMPROVES SURVIVAL; SURGICAL RESECTION; ADJUVANT CHEMOTHERAPY; TUMOR-MARKERS; CA19-9; LEVELS; CANCER; GEMCITABINE; LEWIS; CHEMORADIATION; CLASSIFICATION;
D O I
10.1002/jso.23666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives Identification of prognostic markers is important to establish a perioperative therapeutic strategy for resectable cholangiocarcinoma (CC). The aim of this study was to investigate whether perioperative serum carbohydrate antigen 19-9 (CA19-9) levels can predict survival of patients who underwent surgical resection for CC. Methods The study included 106 patients who underwent surgical resection for CC. Serum CA19-9 levels were measured preoperatively after biliary drainage and postoperatively about 4 weeks after surgery. The association of clinicopathological factors (including perioperative serum CA19-9 levels) with overall survival (OS) was analyzed with univariate and multivariate analyses. Results Differences in OS were significant between groups divided on the basis of two preoperative CA19-9 cutoff values (in U/ml) of 37 and 200 and three postoperative CA19-9 cutoff values (in U/ml) of 37, 100, and 200. In multivariate analysis, absence of postoperative adjuvant chemotherapy (P=0.002), lymph node metastasis (P=0.0002), preoperative CA19-9 (200IU/ml) (P=0.03), and postoperative CA19-9 (37IU/ml) (P<0.0001) were identified as independent predictors of poor OS. Conclusion Both pre- and postoperative serum CA19-9 levels predict the survival of patients with resectable CC, and may contribute to the establishment of a new therapeutic strategy. J. Surg. Oncol. 2014; 110:422-429. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:422 / 429
页数:8
相关论文
共 50 条
[21]   CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma [J].
Loosen, Sven H. ;
Roderburg, Christoph ;
Kauertz, Katja L. ;
Koch, Alexander ;
Vucur, Mihael ;
Schneider, Anne T. ;
Binneboesel, Marcel ;
Ulmer, Tom F. ;
Lurje, Georg ;
Schoening, Wenzel ;
Tacke, Frank ;
Trautwein, Christian ;
Longerich, Thomas ;
Dejong, Cornelis H. ;
Neumann, Ulf P. ;
Luedde, Tom .
SCIENTIFIC REPORTS, 2017, 7
[22]   CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma [J].
Isaksson, Sofi ;
Jonsson, Per ;
Monsef, Nastaran ;
Brunnstrom, Hans ;
Bendahl, Par-Ola ;
Jonsson, Mats ;
Staaf, Johan ;
Planck, Maria .
PLOS ONE, 2017, 12 (10)
[23]   Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma [J].
Boyev, Artem ;
Prakash, Laura R. ;
Chiang, Yi-Ju ;
Newhook, Timothy E. ;
Bruno, Morgan L. ;
Arvide, Elsa M. ;
Dewhurst, Whitney L. ;
Kim, Michael P. ;
Ikoma, Naruhiko ;
Lee, Jeffrey E. ;
Snyder, Rebecca A. ;
Tzeng, Ching-Wei D. ;
Katz, Matthew H. G. ;
Maxwell, Jessica E. .
SURGICAL ONCOLOGY-OXFORD, 2023, 51
[24]   Benign Hydronephrosis and Elevated of Serum Levels of Carbohydrate Antigen CA 19-9: A Case Report [J].
Filipovic, Branka ;
Milinic, Nikola ;
Gacic, Jasna ;
Markovic, Olivera ;
Djokovic, Aleksandra ;
Filipovic, Branislav .
AMERICAN JOURNAL OF CASE REPORTS, 2016, 17 :395-397
[25]   Does the elevation of serum carbohydrate antigen 19-9 level predict poor overall survival in patients with hepatocellular carcinoma? [J].
Wang, Yan-Yan ;
Zhong, Jian-Hong ;
Lu, Zhan ;
Qin, Hong-Gui ;
Li, Le-Qun .
TUMOR BIOLOGY, 2015, 36 (11) :8273-8274
[26]   Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer [J].
Takagi, Chisato ;
Kikuchi, Yutaro ;
Shirakawa, Hirofumi ;
Hoshimoto, Sojun ;
Tomikawa, Moriaki ;
Ozawa, Iwao ;
Hishinuma, Shoichi ;
Ogata, Yoshiro .
ANTICANCER RESEARCH, 2019, 39 (06) :3177-3183
[27]   Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study [J].
Dong, Qian ;
Yang, Xiang-hong ;
Zhang, Yao ;
Jing, Wei ;
Zheng, Li-qiang ;
Liu, Yun-peng ;
Qu, Xiu-juan .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
[28]   Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma [J].
Venkatesh, Preethi G. K. ;
Navaneethan, Udayakumar ;
Shen, Bo ;
McCullough, Arthur J. .
DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (03) :850-857
[29]   Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? [J].
Wang, Jun-Ke ;
Hu, Hai-Jie ;
Shrestha, Anuj ;
Ma, Wen-Jie ;
Yang, Qin ;
Liu, Fei ;
Cheng, Nan-Sheng ;
Li, Fu-Yu .
ONCOTARGET, 2017, 8 (28) :45335-45344
[30]   CA 19-9 Nonproduction Is Associated With Poor Survival After Resection of Pancreatic Adenocarcinoma [J].
Hayman, Amanda V. ;
Stocker, Susan J. ;
Baker, Marshall S. ;
Bentrem, David J. ;
Prinz, Richard A. ;
Marsh, Robert de W. ;
Talamonti, Mark S. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (06) :550-554